Literature DB >> 19524654

Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.

Chandan Thomas1, Vivek Gupta, Fakhrul Ahsan.   

Abstract

This study investigates the efficacy of surface-modified microspheres of hepatitis B surface antigen (HBsAg) in eliciting systemic and mucosal immune responses. Positively charged poly(D,L-lactic-co-glycolic acid) microspheres were prepared by a double-emulsion solvent-evaporation method with cationic agents--stearylamine and polyethylenimine--in the external aqueous phase. Formulations were characterized for morphology, size, density, aerodynamic diameter, entrapment efficiency and in vitro drug-release profile. Immunization was performed after pulmonary administration of the formulations to female Sprague-Dawley rats and the immune response was monitored by measuring IgG levels in serum and secretory (sIgA) levels in salivary, vaginal and bronchoalveolar lavage fluids. The cell-mediated immune response was studied by measuring cytokine levels in spleen homogenates, and a cytotoxicity study was performed with Calu-3 cell line. The aerodynamic diameter of the particles was within the respirable range, with the exception of stearylamine-modified particles. Zeta potential values moved from negative (-6.76 mV) for unmodified formulations to positive (+0.515 mV) for polyethylenimine-modified particles. Compared to unmodified formulations, polyethylenimine-based formulations showed continuous release of antigen over a period of 28-42 days and increased levels of IgG in serum and sIgA in salivary, vaginal and bronchoalveolar lavage. Further, cytokine levels-interferon gamma and interleukin-2-were increased in spleen homogenates. The viability of Calu-3 cells was not adversely affected by the microparticles. In summation, this study establishes that positive surface charges on poly(D,L-lactic-co-glycolic acid) particles containing HBsAg enhances both the systemic and mucosal immune response upon immunization via the respiratory route.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524654     DOI: 10.1016/j.ijpharm.2009.06.006

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  27 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells.

Authors:  Liang Chen; Joseph M Mccrate; James C-M Lee; Hao Li
Journal:  Nanotechnology       Date:  2011-02-02       Impact factor: 3.874

Review 3.  Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.

Authors:  Jardin Leleux; Alexandra Atalis; Krishnendu Roy
Journal:  J Control Release       Date:  2015-10-20       Impact factor: 9.776

4.  Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection.

Authors:  Lori W Norton; Jaehyung Park; Julia E Babensee
Journal:  J Control Release       Date:  2010-06-02       Impact factor: 9.776

5.  In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery.

Authors:  Yen Cu; Carmen J Booth; W Mark Saltzman
Journal:  J Control Release       Date:  2011-07-08       Impact factor: 9.776

6.  Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.

Authors:  Chandan Thomas; Vivek Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

Review 7.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

8.  Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system.

Authors:  Hui Xie; Jeffrey W Smith
Journal:  J Nanobiotechnology       Date:  2010-08-13       Impact factor: 10.435

9.  Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles.

Authors:  Shashi Prasad; Virginia Cody; Jennifer K Saucier-Sawyer; Tarek R Fadel; Richard L Edelson; Martin A Birchall; Douglas J Hanlon
Journal:  Pharm Res       Date:  2012-07-14       Impact factor: 4.200

Review 10.  Use of lectin-functionalized particles for oral immunotherapy.

Authors:  Susanne C Diesner; Xue-Yan Wang; Erika Jensen-Jarolim; Eva Untersmayr; Franz Gabor
Journal:  Ther Deliv       Date:  2012-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.